Atossa Therapeutics Plunges 17% Following $4.5M Offering
Atossa Therapeutics shares faced significant downward pressure today after the clinical-stage biopharmaceutical firm announced a public stock offering valued at $4.5 million. The move, which aims to bolster the company’s capital reserves for ongoing research and development, triggered investor concern regarding potential equity dilution. Markets responded sharply to the news, pushing the stock lower as shareholders reacted to the increased share count.